High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease

V. Bonfante, S. Viviani, L. Devizzi, A. Di Russo, M. Di Nicola, M. Magni, P. Matteucci, S. Grisanti, P. Valagussa, G. Bonadonna, A. M. Gianni

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In an effort to improve results in patients with relapsed or refractory Hodgkin's disease (HD), an intensive regimen combining vinorelbine (25 mg/m2 i.v. days 1 and 5) and high-doses of ifosfamide (3000 mg/m2/d, days 1-4 by continuous infusion) with mesna uroprotection and G-CSF support was designed. Forty-seven patients were treated; 14 had failure to initial induction therapy and 33 had disease relapsed from an initial response. The response rate was 83%, with 21 complete (45%, CR) and 18 partial remissions (38%, PR). Partial response was achieved after a median of two cycles (range 1-3) and CR after a median of six cycles (range 2-10). At the end of ifosfamide and vinorelbine, 10 patients in CR, one in PR, and one with stable disease also received radiotherapy to nodal sites of relapse. Eleven patients who had undergone peripheral blood stem cell (PBSC) harvesting following ifosfamide-vinorelbine proceeded to receive high-dose chemotherapy (HDCT) and PBSC transplantation. The main toxic effect was grade III-IV neutropenia, documented in 65% of cycles with a median duration of 4 days, and non-haematological toxicity was mild. The combination of high-doses of ifosfamide and vinorelbine was well tolerated and an active regimen in treatment of patients with relapsed and refractory HD. It was not only useful as salvage therapy with or without consolidative radiotherapy but it also was a valuable induction regimen before high-dose intensification therapy followed by PBSC reinfusion in patients eligible for this approach.

Original languageEnglish
Pages (from-to)51-55
Number of pages5
JournalEuropean Journal of Haematology, Supplement
Volume61
Issue number64
Publication statusPublished - 2001

Fingerprint

Salvage Therapy
Ifosfamide
Hodgkin Disease
Radiotherapy
Mesna
Peripheral Blood Stem Cell Transplantation
Poisons
Granulocyte Colony-Stimulating Factor
Neutropenia
vinorelbine
Therapeutics
Recurrence
Drug Therapy

Keywords

  • Hodgkin's disease
  • Ifosfamide
  • Refractory
  • Relapsed
  • Salvage therapy
  • Vinorelbine

ASJC Scopus subject areas

  • Hematology

Cite this

High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. / Bonfante, V.; Viviani, S.; Devizzi, L.; Di Russo, A.; Di Nicola, M.; Magni, M.; Matteucci, P.; Grisanti, S.; Valagussa, P.; Bonadonna, G.; Gianni, A. M.

In: European Journal of Haematology, Supplement, Vol. 61, No. 64, 2001, p. 51-55.

Research output: Contribution to journalArticle

@article{49f0e42ea3944f8d96e8ef83a5808b51,
title = "High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease",
abstract = "In an effort to improve results in patients with relapsed or refractory Hodgkin's disease (HD), an intensive regimen combining vinorelbine (25 mg/m2 i.v. days 1 and 5) and high-doses of ifosfamide (3000 mg/m2/d, days 1-4 by continuous infusion) with mesna uroprotection and G-CSF support was designed. Forty-seven patients were treated; 14 had failure to initial induction therapy and 33 had disease relapsed from an initial response. The response rate was 83{\%}, with 21 complete (45{\%}, CR) and 18 partial remissions (38{\%}, PR). Partial response was achieved after a median of two cycles (range 1-3) and CR after a median of six cycles (range 2-10). At the end of ifosfamide and vinorelbine, 10 patients in CR, one in PR, and one with stable disease also received radiotherapy to nodal sites of relapse. Eleven patients who had undergone peripheral blood stem cell (PBSC) harvesting following ifosfamide-vinorelbine proceeded to receive high-dose chemotherapy (HDCT) and PBSC transplantation. The main toxic effect was grade III-IV neutropenia, documented in 65{\%} of cycles with a median duration of 4 days, and non-haematological toxicity was mild. The combination of high-doses of ifosfamide and vinorelbine was well tolerated and an active regimen in treatment of patients with relapsed and refractory HD. It was not only useful as salvage therapy with or without consolidative radiotherapy but it also was a valuable induction regimen before high-dose intensification therapy followed by PBSC reinfusion in patients eligible for this approach.",
keywords = "Hodgkin's disease, Ifosfamide, Refractory, Relapsed, Salvage therapy, Vinorelbine",
author = "V. Bonfante and S. Viviani and L. Devizzi and {Di Russo}, A. and {Di Nicola}, M. and M. Magni and P. Matteucci and S. Grisanti and P. Valagussa and G. Bonadonna and Gianni, {A. M.}",
year = "2001",
language = "English",
volume = "61",
pages = "51--55",
journal = "Scandinavian journal of haematology. Supplementum",
issn = "0902-4506",
publisher = "Wiley-Blackwell",
number = "64",

}

TY - JOUR

T1 - High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease

AU - Bonfante, V.

AU - Viviani, S.

AU - Devizzi, L.

AU - Di Russo, A.

AU - Di Nicola, M.

AU - Magni, M.

AU - Matteucci, P.

AU - Grisanti, S.

AU - Valagussa, P.

AU - Bonadonna, G.

AU - Gianni, A. M.

PY - 2001

Y1 - 2001

N2 - In an effort to improve results in patients with relapsed or refractory Hodgkin's disease (HD), an intensive regimen combining vinorelbine (25 mg/m2 i.v. days 1 and 5) and high-doses of ifosfamide (3000 mg/m2/d, days 1-4 by continuous infusion) with mesna uroprotection and G-CSF support was designed. Forty-seven patients were treated; 14 had failure to initial induction therapy and 33 had disease relapsed from an initial response. The response rate was 83%, with 21 complete (45%, CR) and 18 partial remissions (38%, PR). Partial response was achieved after a median of two cycles (range 1-3) and CR after a median of six cycles (range 2-10). At the end of ifosfamide and vinorelbine, 10 patients in CR, one in PR, and one with stable disease also received radiotherapy to nodal sites of relapse. Eleven patients who had undergone peripheral blood stem cell (PBSC) harvesting following ifosfamide-vinorelbine proceeded to receive high-dose chemotherapy (HDCT) and PBSC transplantation. The main toxic effect was grade III-IV neutropenia, documented in 65% of cycles with a median duration of 4 days, and non-haematological toxicity was mild. The combination of high-doses of ifosfamide and vinorelbine was well tolerated and an active regimen in treatment of patients with relapsed and refractory HD. It was not only useful as salvage therapy with or without consolidative radiotherapy but it also was a valuable induction regimen before high-dose intensification therapy followed by PBSC reinfusion in patients eligible for this approach.

AB - In an effort to improve results in patients with relapsed or refractory Hodgkin's disease (HD), an intensive regimen combining vinorelbine (25 mg/m2 i.v. days 1 and 5) and high-doses of ifosfamide (3000 mg/m2/d, days 1-4 by continuous infusion) with mesna uroprotection and G-CSF support was designed. Forty-seven patients were treated; 14 had failure to initial induction therapy and 33 had disease relapsed from an initial response. The response rate was 83%, with 21 complete (45%, CR) and 18 partial remissions (38%, PR). Partial response was achieved after a median of two cycles (range 1-3) and CR after a median of six cycles (range 2-10). At the end of ifosfamide and vinorelbine, 10 patients in CR, one in PR, and one with stable disease also received radiotherapy to nodal sites of relapse. Eleven patients who had undergone peripheral blood stem cell (PBSC) harvesting following ifosfamide-vinorelbine proceeded to receive high-dose chemotherapy (HDCT) and PBSC transplantation. The main toxic effect was grade III-IV neutropenia, documented in 65% of cycles with a median duration of 4 days, and non-haematological toxicity was mild. The combination of high-doses of ifosfamide and vinorelbine was well tolerated and an active regimen in treatment of patients with relapsed and refractory HD. It was not only useful as salvage therapy with or without consolidative radiotherapy but it also was a valuable induction regimen before high-dose intensification therapy followed by PBSC reinfusion in patients eligible for this approach.

KW - Hodgkin's disease

KW - Ifosfamide

KW - Refractory

KW - Relapsed

KW - Salvage therapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0034743476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034743476&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 51

EP - 55

JO - Scandinavian journal of haematology. Supplementum

JF - Scandinavian journal of haematology. Supplementum

SN - 0902-4506

IS - 64

ER -